Patients with Breast, Colorectal, and Pancreatic Cancers With ATM, CHEK2, or PALB2 PVs Have Similar Mortality to the Average Genetically Tested Patients By Ogkologos - March 18, 2025 855 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a population-based study Source RELATED ARTICLESMORE FROM AUTHOR Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Relacorilant Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... MOST POPULAR Mylan Recalls Injectable Cancer Drug After Particulates Discovered March 20, 2019 Inequalities cause 2,000 extra cancer cases in Wales June 8, 2023 Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic... May 14, 2026 How Clinical Trials Can Lead to Life-Saving Treatment: The TAPUR Trial... October 12, 2023 Load more HOT NEWS A Penny for Your Thoughts Study Suggests Reviewing Lung Cancer Screening Criteria for African Americans Fosnetupitant Is Valuable in the Prophylaxis of Acute, Delayed, and Beyond... Join the Great American Smokeout for a Healthier Tomorrow
